98%
921
2 minutes
20
Infectious endophthalmitis is a severe intraocular infection caused by bacteria, or less commonly by fungi. It can occur after penetrating eye procedures, trauma, or the spread of infection from contiguous structures or via emboli from distant organs. Because of the time-critical nature of the treatment, endophthalmitis is treated with the clinical diagnosis and modified by the microbiological report of the intraocular contents. The current strategy for managing endophthalmitis relies on pre-clinical literature, case series, and one large multi-center randomized clinical trial on post-cataract surgery endophthalmitis. Culture-susceptibility of the microorganisms from undiluted vitreous guides the definitive treatment in non-responsive cases. Strategies to reduce the incidence of endophthalmitis after penetrating eye procedures have been developed concurrently with refined means of treatment. Despite these advances, outcomes remain poor for many patients. Although consensus articles have been published on managing endophthalmitis, treatment patterns vary, and controversies remain. These include (1) the use of newer methods for early and precise microbiological diagnosis; (2) the choice of intravitreal antibiotics; (3) the need for systemic therapy; (4) early and complete vitrectomy. Here, we review the current consensus and address controversies in diagnosing and managing endophthalmitis. This review is intended to familiarize physicians and ophthalmologists with different aspects of endophthalmitis management to make informed decisions.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1016/j.preteyeres.2023.101218 | DOI Listing |
Infect Drug Resist
September 2025
Department of Emergency Medicine, Affiliated Lu'an Hospital of Anhui Medical University, Lu'an, Anhui, 237005, People's Republic of China.
Hypervirulent is a recently identified pathotype characterized by high virulence and rapid dissemination. It is associated with invasive infections at multiple anatomical sites, including liver abscesses, necrotizing fasciitis, meningitis, myositis, and endophthalmitis. It has emerged as a significant threat to public health due to its aggressive clinical course and high mortality rate.
View Article and Find Full Text PDFJ Vitreoretin Dis
September 2025
The Royal Victorian Eye and Ear Hospital, Melbourne, Australia.
To perform a cost-utility analysis comparing primary pars-plana vitrectomy (PPV) within 24 hours with primary nonsurgical vitreous tap (or tap and inject [T&I]) for the management of endophthalmitis. Retrospective cost-utility analysis using decision tree modeling. The Victorian Endophthalmitis Registry was used to model outcome probabilities and costs from a third-party payer perspective.
View Article and Find Full Text PDFOphthalmol Retina
September 2025
The University of Ottawa Eye Institute, Ottawa, Ontario, Canada. Electronic address:
Objective: Anti-vascular endothelial growth factor (VEGF) therapies have transformed the management of neovascular age-related macular degeneration, diabetic macular edema, and macular edema secondary to retinal vein occlusion (RVO). This class-wide pharmacovigilance study evaluated the disproportionality of reported ocular adverse events (AEs) among anti-VEGF agents using real-world data.
Design: A population-based, observational pharmacovigilance study.
Jpn J Ophthalmol
September 2025
Department of Ophthalmology, Gifu University School of Medicine Graduate School of Medicine, Gifu, Japan.
Purpose: To identify novel risk factors associated with the presence of fungal ocular lesions in patients with fungemia and to evaluate the validity and efficacy of routine screening.
Study Design: Retrospective study METHODS: The medical records of 198 patients diagnosed with fungemia by blood culture at 3 medical centers in Japan between March 2017 and April 2022 were analyzed. Ocular lesions were categorized as possible, probable, or proven, according to previously established definitions.
Br J Ophthalmol
August 2025
Dr. Rajendra Prasad Centre for Ophthalmic Sciences, All India Institute of Medical Sciences, New Delhi, Delhi, India
Anti-vascular endothelial growth factor (anti-VEGF) agents have demonstrated efficacy and short-term safety in the treatment of retinopathy of prematurity (ROP), establishing them as the preferred option for zone I and zone II posterior disease. Despite their advantages, the effects of anti-VEGF agents are relatively temporary. Consequently, ROP may reactivate or recur if retinal vascularisation has not sufficiently progressed and significant areas of avascular anterior retina remain while the anti-VEGF agents are cleared from the vitreous cavity.
View Article and Find Full Text PDF